Michele Moschetta, Global Clinical Head, Late Development Oncology, Barcelona Global Hub at AstraZeneca, shared on LinkedIn:
“A few oncology updates that caught my attention this week.
INTerpath-001
INTerpath-001 is now in NEJM, the first phase 3 readout of an individualised neoantigen mRNA therapy. In 1,137 patients with resected stage IIB–IV melanoma, adding intismeran autogene to adjuvant pembrolizumab raised 24-month RFS from 70.0% to 82.2%. The HR was 0.99 for the first 6 months and 0.42 afterwards, so the benefit seems to appear later. OS is still immature.
Title: Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma
Authors: Georgina V. Long, Muhammad A. Khattak, Helen J. Gogas, Dirk Schadendorf, Ana Arance, Matteo S. Carlino, Piotr Rutkowski, Gareth Rivalland, Antoni Ribas, Janice M. Mehnert, Patrick A. Ott, Reinhard Dummer, Paola Queirolo, Christoffer Gebhardt, Caroline Dutriaux, Carlos Rojas, Yuanbin Chen, Lisa M. Tachiki, Ronnie Shapira-Frommer, Oliver Bechter, Ryan J. Sullivan, Alexander M. M. Eggermont, Laureen S. Ojalvo, Michelle Brown, Jinchun Zhang, Dmitri O. Grebennik, Mizuho Fukunaga-Kalabis, Paolo A. Ascierto, Michele Del Vecchio.
CAMORAL trial
In resectable stage III–IVB HNSCC, the randomised phase 2 CAMORAL trial (n=125) compared perioperative camrelizumab plus chemotherapy with upfront surgery: 2-year EFS 77.8% vs 46.1% (HR 0.34), OS HR 0.25, with more grade ≥3 AEs (79% vs 56%). A small trial at 4 centres in China, so phase 3 confirmation is needed.
Title: Perioperative Camrelizumab Plus Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma – A Randomized Clinical Trial
Authors: Feng Liu, Yanjie Zhang, Hailong Ma, Wenying Zhang, Biying Chen, Jingjing Sun, Jiping Ding, Haihua Yuan, Yanan Wang, Wei Cao, Siyi Li, Jinsong Li, Shizhou Zhang, Yulin Jia, Zhonglong Liu, Wenyuan Dong, Bin Jiang, Yuan Yao, Zheng Pang, Yue He.
daNIS-2
Not every result was positive. In daNIS-2, adding the anti-TGF-β antibody NIS793 to gemcitabine/nab-paclitaxel in metastatic pancreatic cancer worsened OS, 9.2 vs 11.2 months (HR 1.26); the trial stopped early.
Title: daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma
Authors: S. Paulson, M. Ikeda, L. Shen, A. Stein, T. Macarulla, M. Milella, T. Golan, Z. Wainberg, J. Taieb, L. Wang, F. Polydoros, C. Abecunas, E. López, E.M. O’Reilly
Stroma-Sensing Immunotherapy
Meanwhile, preclinical work in Cancer Cell suggests a matrix-anchored TGF-β trap can relieve immune exclusion in mice.
Title: A stroma-sensing TGF-β blockade reprograms CAF-myeloid niches to induce durable tumor immunity
Authors: Dong Woo Kang, Jin Beom Bae, Seonho Yoo, Hyejin Kim, Pyunggang Kim, Jaewoo Mo, Jinhwan Kim, Jin Su Kim, Kwiyeom Yoon, Ye Seon Kim, Jeong Su Lee, June Myoung Kim, Min Gi Kang, Min Jung Lee, Changwon Lim, Isaac Y. Kim, Chang Pyo Hong, Junil Kim, John J. Letterio, Seong-Jin Kim
p53-Targeted T-Cells
From early development: an NCI phase II trial of mutant-p53-specific TCR-T cells with IL-2 and pembrolizumab reported objective responses in 3 of 6 evaluable patients with heavily pretreated colorectal, breast or pancreatic cancer. Small numbers, but an interesting signal for a long ‘undruggable‘ target.
Title: 553 Adoptive transfer of T cells engineered with mutant p53-specific TCRs for the treatment of metastatic solid epithelial cancers: interim report of ongoing phase II clinical trial
Authors: Sanghyun Peter Kim, Noam Levin, Caroline Kellogg, Hyunmi Halas, Rachel K Beyer, Nicholas D Klemen, Mei Li M Kwong, Stephanie L Goff, James C Yang, Steven A Rosenberg
Ovarian Cancer Screening
In early detection, a serum extracellular-vesicle test based on the lncRNA Tu-stroma separated ovarian cancer precursor lesions (STIC) from controls with an AUC of 0.99, vs 0.59 for CA125. Retrospective samples, so prospective validation is needed.
Title: Blood-based RNA biomarker for the early detection of ovarian cancer
Authors: Jochen Wilhelm, Amit Kumar, Hitesh Vasiyani, Narsimha Mamidi, Zhaoyu Sun, Aenya Gogna, Praveen Bhoopathi, Keshav C. Gogna, Chelsea Salyer, Amy Lu, Kranthi Kumar Chougoni, Ava N. Gardner, Andrew S. Poklepovic, Masaki Nagane, Kumari S. Shree, Emad A. Rakha, Karuppaiyah Selvendiran, George L. Maxwell, Jamie N. Bakkum-Gamez, Shariska Petersen Harrington, Elnaz Abbasi Farid, Nadia Traficante, David Bowtell, Christopher D. Collier, Rebecca Z. Drexler, Christine Kramer, Mary M. Mullen, Alexandar Tzankov, Kirsten D. Mertz, Jun Watanabe, Shimpei Nagai, Tatsuyuki Chiyoda, Wataru Yamagami, Kenta Masuda, Elena Garre, Göran Landberg, David L. Kolin, Calla O’Connor, Sarah A. Ackroyd, Bodour Salhia, Paola A. Gehrig, Aanya Singh, Tytus Bernas, Anusha Challa, Sriram Sriperumbuduri, Nolan A. Wages, Jordan Lewis, Lien Hoang, Janice S. Kwon, Jasmin D. Haslbauer, Mark P. Kühnel, T. Rinda Soong, Sarah Taylor, Carlos Zuazo, Tiffany Beck, Michael J. Demeure, Marc R. Radke, Sourat Darabi, Denise Connolly, Barbara S. Norquist, Nozomi Yachida, Kazuaki Suda, Kosuke Yoshihara, Tu-Yung Chang, Patrick Martin, Kyoung Jae Won, Tian-Li Wang, Ie-Ming Shih, Thomas Russell Pisanic, Tanvir K. Dhaliwal, Vandanaa Jayaprakash, Bukola Adeshina, Seungpyo Hong, Ana Blanca, David R. Braxton, Cesar M. Castro, Elizabeth M. Swisher, Allan Tsung, Ernst Lengyel, Susan Domchek, William L. Redmond, Yonglun Luo, Ole Mogensen, Robert A. Winn, Bo R. Rueda, Ronny Drapkin, Andrew K. Godwin, Ronald J. Buckanovich, Kenneth P. Nephew, Rafael J. Luque, Antonio Lopez-Beltran, Robert L. Coleman, Daniel Von Hoff, David Sidransky, Maximilian Ackermann, Danny Jonigk, Steven R. Grossman, Ranjit Manchanda, Rajan Gogna, Esha Madan
FDA Guidance
Finally, FDA draft guidance on early-phase solid-tumour trials (comments until 11 January 2027) makes safety and tolerability the primary aim of first-in-human dose escalation, asks for justified expansion cohorts, discourages upper age limits, and notes that single-arm trials cannot adequately characterise OS or PFS.
See the gallery for the full roundup and all sources.
Looking forward to seeing what next week brings.
Views are my own.”
